During BMS’ earnings call Thursday, CEO Chris Boerner, Ph.D., described Cobenfy as “delivering steady growth.” But the first-in-class drug still has a long way to go to fulfill its promise as a ...
Bristol Myers Squibb beat analyst and consensus estimates for the third quarter with $12.2 billion in sales, but executives ...
Cobenfy represents a breakthrough schizophrenia treatment with a novel mechanism, but limited long-term data requires ...
MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its ...
The head of the Food and Drug Administration’s drug center abruptly resigned Sunday amid concerns about his personal conduct.
4don MSN
FDA to streamline approvals for generic biological drugs in latest move targeting health costs
The US Food and Drug Administration will take steps to streamline the process to develop generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback